Acute exenatide (Byetta®) poisoning was not associated with significant hypoglycemia

Clinical Toxicology

Volumn 46, Issue 4, 2008, Pages 346-347

  Cohen, Victor ^a,b   Teperikidis, Eleftherios ^b   Jellinek, Samantha P ^b   Rose, Jonathan ^b  

^a LONG ISLAND UNIVERSITY   (United States)

^b MAIMONIDES MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLUCOSE; METOCLOPRAMIDE;

ADULT; CASE REPORT; DRUG INTOXICATION; DRUG OVERDOSE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; LETTER; MORBID OBESITY; SUICIDE ATTEMPT;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; OVERDOSE; PEPTIDES; SUICIDE, ATTEMPTED; VENOMS;

EID: 41149122133     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.1080/15563650701517707     Document Type: Letter

References (9)

1. Amylin Pharmaceuticals, Inc. Exenatide prescribing information. Accessed on May 1, 2006 at 〈www.byetta.com〉
2. Calara F, Taylor K, Han J, Zabala E, Moo Car E, Wintle M. A randomized, open label, cross over study examining the effect of injection site bioavailability of exenatide (Synthetic Enedin-4). Clinical Therapeutics 2005; 27(2):210-215.
3. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28(5):1083-91.
4. Degn KB, Brock B, Juhl CB, Djurhuus CB, Grubert J, Kim D, Han J, Taylor K, Fineman M, Schmitz O. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 2004; 53(9):2397-403.
5. Micromedex® Healthcare Series [intranet database]. Version 5.1. Greenwood Village, CO: Thomson Micromedex.
6. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Exanatide-113 clinical study group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27(11):2628-35.
7. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28(5):1092-1100.
8. Amylin Pharmaceuticals, Inc. Accessed on June 22, 2006 at 〈http://www.byetta.com/patient/byetta_pen_122.jsp?reqNavId=2.3〉
9. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30(2):239-45.